Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Optimizing Statin Treatment Decisions for Diabetes Patients in the Presence of Uncertain Future Adherence
Mason, Jennifer, England, Darin, Denton, Brian T., Smith, Steven A., Kurt, Murat , Shah, Nilay D., Denton, Brian T.

Mayo Clinic

Medical Decision Making | April 29, 2011 | Volume: 32 | Issue: 1 | Pages: 154-166

10.1177/0272989x11404076 | PMID 21531901 Get It

Background. Statins are an important part of the treatment plan for patients with type 2 diabetes. However, patients who are prescribed statins often take less than the prescribed amount or stop taking the drug altogether. This suboptimal adherence may decrease the benefit of statin initiation. Objective. To estimate the influence of adherence on the optimal timing of statin initiation for patients with type 2 diabetes. Method. The authors use a Markov decision process (MDP) model to optimize the treatment decision for patients with type 2 diabetes. Their model incorporates a Markov model linking adherence to treatment effectiveness and long-term health outcomes. They determine the optimal time of statin initiation that minimizes expected costs and maximizes expected quality-adjusted life years (QALYs). Results. In the long run, approximately 25% of patients remain highly adherent to statins. Based on the MDP model, generic statins lower costs in men and result in a small increase in costs in women relative to no treatment. Patients are able to noticeably increase their expected QALYs by 0.5 to 2 years depending on the level of adherence. Conclusions. Adherence-improving interventions can increase expected QALYs by as much as 1.5 years. Given suboptimal adherence to statins, it is optimal to delay the start time for statins; however, changing the start time alone does not lead to significant changes in costs or QALYs.
Preliminary Experience and Development of an Algorithm for the Optimal Use of the Laparoscopic Component Separation Technique for Myofascial Advancement During Ventral Incisional Hernia Repair
Bray, Jillian M., Pfluke, Jason M., Asbun, Horacio J. , Smith, C. Daniel, Bowers, Steven P. , Parker, Michael J.

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | April 27, 2011 | Volume: 21 | Issue: 5 | Pages: 405-410

10.1089/lap.2010.0490 | PMID 21524200 Get It

Re: Ultrasound Estimated Bladder Weight and Measurement of Bladder Wall Thickness—Useful Noninvasive Methods for Assessing the Lower Urinary Tract?
Jacobson, Debra J., Sauver, Jennifer L. St. , Jacobsen, Steven J. , Rule, Andrew D. , St Sauver, Jennifer L

Mayo Clinic

Journal of Urology | April 24, 2011 | Volume: 185 | Issue: 6 | Pages: 2435-2435

10.1016/j.juro.2011.02.031 | PMID 21513957 Get It

Establishment and characterization of a novel Waldenström macroglobulinemia cell line, MWCL-1
Hodge, Lucy S. , Novak, Anne J. , Grote, Deanna M., Braggio, Esteban , Ketterling, Rhett P. , Troska, Tammy L. Price, Ziesmer, Steven C., Fonseca, Rafaël , Morice, William G. , Ansell, Stephen M. , Manske, Michelle K. , Troska, Tammy P., Witzig, Thomas E. , Morice, William George , Gertz, Morie A. , Braggio, Esteban , Ketterling, Rhett P , Fonseca, Rafael

Mayo Clinic

Blood | March 18, 2011 | Volume: 117 | Issue: 19 | Pages: e190-e197

10.1182/blood-2010-12-326868 | PMID 21415268 Get It

Abstract Waldenström macroglobulinemia (WM) is a rare, lymphoplasmacytic lymphoma characterized by hypersecretion of immunoglobulin M (IgM) protein and tumor infiltration into the bone marrow and lymphatic tissue. Our understanding of the mechanisms driving the development and progression of WM is currently by the shortage of representative cell models available for study. We describe here the establishment of a new WM cell line, MWCL-1. Comprehensive genetic analyses have unequivocally confirmed a clonal relationship between this novel cell line and the founding tumor. MWCL-1 cells exhibit an immunophenotype consistent with a diverse, tumor clone composed of both small B lymphocytes and larger lymphoplasmacytic cells and plasma cells: CD3−, CD19+, CD20+, CD27+, CD38+, CD49D+, CD138+, cIgM+, and κ+. Cytogenetic studies identified a monoallelic deletion of 17p13 (TP53) in both the cell line and the primary tumor. Direct DNA resequencing of the remaining copy of TP53 revealed a missense mutation at exon 5 (V143A, GTG>GCG). In accordance with primary WM tumors, MWCL-1 cells retain the ability to secrete high amounts of IgM protein in the absence of an external stimulus. The genetic, immunophenotypic, and biologic data presented here confirm the validity of the MWCL-1 cell line as a representative model of WM.
Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-β
Park, Laibaik , Zhou, Ping , Zhou, Joan, Pitstick, Rose, Previti, Mary Lou , Younkin, Linda H., Younkin, Steven G. , Nostrand, William E. Van , Anrather, Josef , Carlson, George A. , Iadecola, Costantino , Wang, Gang , Cho, Sunghee

Mayo Clinic

Proceedings of the National Academy of Sciences | March 8, 2011 | Volume: 108 | Issue: 12 | Pages: 5063-5068

10.1073/pnas.1015413108 | PMID 21383152 Get It

Increasing evidence indicates that cerebrovascular dysfunction plays a pathogenic role in Alzheimer's dementia (AD). Amyloid-β (Aβ), a peptide central to the pathogenesis of AD, has profound vascular effects mediated, for the most part, by reactive oxygen species produced by the enzyme NADPH oxidase. The mechanisms linking Aβ to NADPH oxidase-dependent vascular oxidative stress have not been identified, however. We report that the scavenger receptor CD36, a membrane glycoprotein that binds Aβ, is essential for the vascular oxidative stress and neurovascular dysfunction induced by Aβ 1–40 . Thus, topical application of Aβ 1–40 onto the somatosensory cortex attenuates the increase in cerebral blood flow elicited by neural activity or by endothelium-dependent vasodilators in WT mice but not in CD36-null mice (CD36 0/0 ). The cerebrovascular effects of infusion of Aβ 1–40 into cerebral arteries are not observed in mice pretreated with CD36 blocking antibodies or in CD36 0/0 mice. Furthermore, CD36 deficiency prevents the neurovascular dysfunction observed in transgenic mice overexpressing the Swedish mutation of the amyloid precursor protein Tg2576 despite elevated levels of brain Aβ 1–40 . CD36 is also required for the vascular oxidative stress induced by exogenous Aβ 1–40 or observed in Tg2576 mice. These observations establish CD36 as a key link between Aβ 1–40 and the NADPH oxidase-dependent vascular oxidative stress underlying the neurovascular dysfunction and suggest that CD36 is a potential therapeutical target to counteract the cerebrovascular dysfunction associated with Aβ.
The Effects of Body Mass Index on Changes in Prostate-Specific Antigen Levels and Prostate Volume Over 15 Years of Follow-up: Implications for Prostate Cancer Detection
Wallner, Lauren P. , Morgenstern, Hal, McGree, Michaela E. , Jacobson, Debra J., Sauver, Jennifer L. St. , Jacobsen, Steven J. , Sarma, Aruna V. , St Sauver, Jennifer L

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 8, 2011 | Volume: 20 | Issue: 3 | Pages: 501-508

10.1158/1055-9965.epi-10-1006 | PMID 21242331 Get It

Abstract Objective: To investigate the association of body mass index (BMI) and BMI change with change in prostate-specific antigen (PSA) level and to assess the possible roles of PSA hemodilution and prostate volume in explaining the obesity and PSA association. Methods: In 1990, a randomly selected cohort of Caucasian men, aged 40 to 79 years, from Olmsted County, Minnesota, completed questionnaires ascertaining demographic characteristics, current medical conditions, and medications biennially, with a subset undergoing blood draws and clinical examinations. Linear mixed models were used to predict annual changes and intercepts of individual changes in BMI, PSA, prostate volume, plasma volume, and PSA mass, adjusting for age in 545 men with at least 2 serial PSA, BMI, and prostate volume measurements. Results: Baseline BMI was inversely associated with the annual percent change in PSA, adjusting for age, baseline PSA, and prostate volume and for the rates of change in BMI and prostate volume (β = −0.003, 95% CI: −0.006 to −0.0003). Baseline obesity was positively associated with mean baseline levels and the rate of change in prostate volume (P = 0.002) and plasma volume (both P < 0.001) but was not associated with either the mean baseline values or the rate of change in PSA mass. Conclusions: Baseline obesity was associated with baseline PSA and prostate volume and with the rate of change in PSA over 15 years of follow-up. Impact: The inverse association of obesity with prostate cancer diagnosis may be at least partly due to detection bias, which is due to larger prostate volumes and PSA hemodilution in obese men. Cancer Epidemiol Biomarkers Prev; 20(3); 501–8. ©2011 AACR.
Abstract 2145: Identification of genomic alterations and integrated gene expression profiles for MSS colon tumors
Loo, Lenora W. M. , Tiirikainen, Maarit , Okimoto, Gordon , Lum‐Jones, Annette, Seifried, Ann, Gallinger, Steven , Thibodeau, Steven, Cheng, Iona C. , Casey, Graham , Marchand, Loı̈c Le

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 2145-2145

10.1158/1538-7445.am10-2145 Get It

Abstract Colon cancer is the result of a multi-step process involving the accumulation of genetic and epigenetic alterations leading to the transformation of normal colon epithelium to adenocarcinoma. Identification of characteristic genetic alterations is of critical importance to increase our understanding of the transformation process. We focused our analysis on the most common molecular sub-type of colon cancers, microsatellite stable (MSS) and CpG island methylator phenotype (CIMP)-negative, to identify characteristic copy number alteration (CNA) events and associated gene expression profiles using high-resolution genome-wide microarrays. DNA and RNA were extracted from 41 fresh-frozen paired colon tumors and adjacent normal tissue collected by the Colon Cancer Family Registry. Genomic profiles, such as CNAs and loss of heterozygosity (LOH), were identified with the Affymetrix Genome-Wide Human SNP 6.0 array for both tumor and adjacent normal tissue. Gene expression profiles of tumors and adjacent normal tissue were identified with the Affymetrix GeneChip Human Exon 1.0 ST array. Partek Genomics Suite software was used for analysis and data integration. We identified recurrent (>25%) CNAs in several chromosomal regions: gain in 1q, 7p, 7q, 8q, 13q, 20p, 20q, Xp, Xq and loss in 5q, 8p, 14q, 16p, 17p, 18p, and 18q. In addition, based on the allele information from the SNP arrays, we found a subset of these recurrent CNAs were associated with LOH. Preliminary results from the integration of CNA and gene expression data in tumors indicate that a subset of these recurrent CNAs is associated with the disruption of gene expression. For example, we observed recurrent copy number gain in 8q24.21, the genomic region containing the c-MYC gene, and associated up-regulation of c-MYC gene expression in tumors compared to adjacent normal tissue. In another example, recurrent copy number loss at 5q22.2 was associated with down-regulation of APC gene expression; loss of function of this tumor suppressor is associated with both hereditary and sporadic colon cancer. This genome-wide characterization of both genomic alterations and gene expression may help identify key genes and pathways that are disrupted in this common molecular subtype of colon cancer. We will present detailed results from this integrated and comprehensive genetic profiling of MSS and CIMP-negative colon cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2145.
Are e-Health Web Users Looking for Different Symptom Information Than Callers to Triage Centers?
North, Frederick , Varkey, Prathibha, Laing, Brian Yoshio, Cha, Steven S., Tulledge‐Scheitel, Sidna M. , Cha, Steven S.

Mayo Clinic

Telemedicine and e-Health | January 7, 2011 | Volume: 17 | Issue: 1 | Pages: 19-24

10.1089/tmj.2010.0120 | PMID 21214306 Get It

Introduction: Telemedicine options for symptom assessment include both telephonic means (call centers) and Internet sites. Although symptom assessment call centers have been available for decades, symptom assessment over the Internet is relatively new. It is not well known what types of symptoms Internet users are seeking assessment for and whether extant telephone triage algorithms would be applicable to Internet users. Methods: Symptom assessments on a heavily used Internet site ( MayoClinic.com ) were compared with symptom calls to a U.S. call center (Ask Mayo Clinic). Results: Internet users sought symptom assessments about adult symptoms 13 times more often than children's symptoms. In contrast, over the telephone, adult symptoms were addressed 2.1 times more frequently than children's symptoms. Despite the differences in frequencies of adult and child symptom assessments, users of the Internet and telephone callers asked about specific symptoms with similar relative frequencies. Analysis of 20 adult symptom types shared by the Web and call center revealed that by excluding only 2 assessments (nasal symptoms and leg pain) the remaining 18 showed a significant correlation in counts of use ( r 2 = 0.68, p < 0.001 for linear trend). Conclusions: Internet users have symptoms assessed in similar proportions to callers, with a few exceptions. Compared with callers, Web users are much more likely looking for information about adult symptoms. Callers are proportionally asking more about acute symptoms, whereas Internet users appear more interested in symptom assessment of chronic conditions.
Ultrasonic Shears in Free‐Tissue Transfer
Koch, Cody A., Olsen, Steven M., Martin, Eliot J., Moore, Eric J.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | December 30, 2010 | Volume: 144 | Issue: 2 | Pages: 201-205

10.1177/0194599810391846 | PMID 21493416 Get It

ObjectiveThe harvest of some microvascular free flaps for head and neck reconstruction entails tedious and time‐consuming dissection of multiple perforating vessels and/or muscular attachments. The objective of this study is to investigate the use of ultrasonic shears as a means to decrease operative time and increase surgical efficiency in the harvest of microvascular free flaps.Study DesignProspective cohort study.SettingTertiary referral center.Subjects and MethodsA prospective study of all people undergoing fibula (FFF) or anterolateral thigh (ALT) free flap reconstruction of head and neck defects was conducted from October 1, 2005, through December 30, 2009.ResultsThere were 69 FFF and 39 ALT free flaps performed by a single surgeon during the study period. Ultrasonic shears were used in 53 (76.8%) FFF and 26 (80.6%) ALT free flaps, whereas traditional dissection techniques were used in 16 (23.2%) FFF and 13 (19.4%) ALT free flaps. The use of ultrasonic shears significantly decreased the harvest time of FFF and ALT free flaps an average of 14.5 and 16.3 minutes, respectively. The average cost savings associated with the use of ultrasonic shears was $492 for FFF and $543 for ALT free flaps compared to traditional dissections techniques. Similar rates of complications were observed when ultrasonic shears were used compared to traditional techniques.ConclusionsThe use of ultrasonic shears in the harvest of microvascular free flaps decreases operative time, leading to significantly decreased costs without an increased risk of complications compared to traditional dissection techniques.
Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7
Nikcevich, Daniel A., Sloan, Jeff A. , Kugler, John W., Silberstein, Peter T., Dentchev, Todor, Wender, Donald B., Novotny, Paul J. , Chitaley, Umesh, Loprinzi, Charles L. , Grothey, Axel , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | December 29, 2010 | Volume: 29 | Issue: 4 | Pages: 421-427

10.1200/jco.2010.31.5911 | PMID 21189381 Get It

Purpose Cumulative sensory neurotoxicity (sNT) is the dose-limiting toxicity of oxaliplatin, which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant settings. In a nonrandomized, retrospective study, intravenous (IV) calcium/magnesium (Ca/Mg) was associated with reduced oxaliplatin-induced sNT. Methods Patients with colon cancer undergoing adjuvant therapy with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) were randomly assigned to Ca/Mg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo, in a double-blinded manner. The primary end point was the percentage of patients with grade 2 or greater sNT at any time during or after oxaliplatin-based therapy by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; version 3) criteria. An oxaliplatin-specific sNT scale and patient questionnaires were also used to assess sNT. After 104 of 300 planned patients were enrolled, the study was closed. This was due to preliminary reports from another trial that suggested that Ca/Mg decreased treatment efficacy; these data were subsequently found to be incorrect. Results Overall, 102 patients were available for analysis. Ca/Mg decreased the incidence of chronic, cumulative, grade 2 or greater sNT, as measured by NCI CTCAE (P = .038) and also by the oxaliplatin-specific sNT scale (P = .018). In addition, acute muscle spasms associated with oxaliplatin were significantly reduced (P = .01) No effect on acute, cold-induced sNT was found. No substantial differences in adverse effects were noted between Ca/Mg and placebo. Conclusion Despite early termination and decreased statistical power, this study supports IV Ca/Mg as an effective neuroprotectant against oxaliplatin-induced cumulative sNT in adjuvant colon cancer.